FREE Account Opening + No Clearing Fees

Family Care RI review (Avoid)

Family Care Hospitals Limited Logo

•    FCHL is the healthcare treatment, imaging, and lab test services provider. 
•    It is operating in a highly competitive and fragmented segment. 
•    As of September 30, 2022, it had negative reserves which is a major concern. 
•    Promoter's holding is down from 42.39% to 13.74% in the last three quarters.
•    There is no harm in skipping this RI as it's a High-Risk/Low Return bet. 

Family Care Hospitals Ltd. (FCHL) - the company that was originally promoted at Pharma Offset Ltd. changed its name to Pharma Com (India) Ltd., to Count N Denier (India) Ltd., to Scandent Imaging Ltd., and then finally to Family Care Hospitals Ltd. Thus it kept rechristening itself so far. 

FCHL is currently operating a hospital under the name of "Family Care Hospitals" at Mira Road East, Thane, Maharashtra and is also operating 9 (Nine) imaging centres across the Mumbai Metropolitan region.  These imaging centres provide scanning solutions to ENT and Dental healthcare professionals with information to help them establish or support diagnoses and prescribe medication and treatment for patient care. 

For the convenience of patients, it provides value-added services such as a home collection of specimens, house calls, and various other service delivery or access modes (i.e., at diagnostic centres, SMS, email, web, and mobile portal) for tests and thereafter access for reports. As of September 30, 2022, it had 154 employees on its payroll, and as of October 31, 2022, it was operating with a 100-bed capacity. It is operating from 11 leased properties at various places in Thane and Mumbai. 

The company is coming out with its Rights Issue (RI) of 40767000 equity shares of Rs. 10 each at a fixed price of Rs. 12 per share to mobilize Rs. 48.92 cr. It is offering RI in the ratio of 127 shares for every 100 shares held as of the record date of January 03, 2023, to the eligible stakeholders. The issue opens for subscription on January 23, 2023, and will close on February 07, 2023. The full amount is to be paid along with the application for the number of shares applied. Post allotment, shares will be listed on BSE. The company is spending Rs. 0.47 cr. for this RI process and from the net proceeds, it will utilize Rs. 12.75 cr. for branding and marketing expenses, Rs. 24.50 cr. for the working capital, and Rs. 11.20 cr. for general corporate purposes. 

Fedex Securities Pvt. Ltd. is the sole lead manager to this RI and Purva Sharegistry (India) Pvt. Ltd. is the registrar of the issue. 

Post RI, FCHL's current paid-up equity capital of Rs. 32.10 cr. will stand enhanced to Rs. 72.87 cr. Based on the RI pricing, the company is looking for a market cap of Rs. 87.44 cr.  

On the financial performance front, for the last three fiscals, FCHL has posted a turnover/net profit of Rs. 13.26 cr. / Rs. 0.03 cr. (FY20), Rs. 35.37 cr. / Rs. 4.07 cr. (FY21), and Rs. 42.38 cr. / Rs. 5.20 cr. (FY22). 

As per unaudited results submitted to BSE, for the first half of FY23, it earned a net profit of Rs.2.76 cr. on a turnover of Rs. 23.11 cr. Due to accumulated carried forward losses from its previous operations, as of September 30, 2022, its paid-up equity capital of Rs. 32.10 cr. had negative reserves of Rs. - (15.10) cr. and is a major concern.

It announced a dividend of 1% (FY22) and an interim dividend of 0.5% (FY23) in July 2022 and November 2022 respectively for FY22. This is a bit surprising as its NAV is in red.  It will adopt a prudent dividend policy post-listing of RI, based on its financial performance and future prospects. 

The scrip last closed on cum-right basis at Rs. 14.08 on January 02, 2023, and opened on an ex-right basis at Rs. 13.90 on January 03, 2023. Since then, it has marked a high/low of Rs. 15.40 / Rs. 13.05. It last closed at Rs. 13.25 as of January 20, 2023. For the last 52 weeks, it has marked a high/low of Rs. 53.32/ Rs. 10.55. The promoter's holding is declined from 42.39% as of June 30, 2022, to 13.74% as of December 31, 2022, and raises a concern. The counter is well maintained above the RI price to lure investors.

Conclusion / Investment Strategy

This company has frequently changed its name and operational activities. As of September 30, 2022, its current paid-up equity capital of Rs. 32.10 cr. had negative reserves of Rs. – (15.10) cr. and thus it has a negative NAV. More than doubled post-RI equity base may pose servicing issues. There is no harm in skipping this RI as it’s a high-risk/low-return bet.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on January 20, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. My reviews do not cover GMP market and operators game plans. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in stock markets is subject to unpredictable market-related risks. The above information is based on RHP and other documents available as of date coupled with market perception. The author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda, a freelance journalist

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

More Family Care Hospitals Limited RI Views / Analysis / Recommendations ...

The Family Care Hospitals Rights Issue 2022 Analysis helps you to understand about the company, offer detail, valuation, capital structure and financial performance. Our SEBI registered Rights Issue Analysts tells you if Family Care Hospitals Rights Issue 2022 worth investing. The Family Care Hospitals Rights Issue 2022 Note sets the Rights Issue expectations in systematic way which tells you if Family Care Hospitals Rights Issue 2022 good to buy (good or bad / yes or no). The Rights Issue Forecast tells you weather to invest in Family Care Hospitals Rights Issue 2022 by providing Rights Issue recommendations i.e. subscribe, avoid and neutral.


4. Pravin Birhade     Link|January 24, 2023 10:57:56 AM
Family care hospital is caring and treat us like family members... Good company to invest.
3. Shridhar Sanjay Koparkar     Link|January 24, 2023 10:53:17 AM
We are very happy and satisfied with the service and the behavior of the entire hospital staffs and doctors ..
family care hospitals limited is my right investment decision.
2. Hemantsingh     Link|January 24, 2023 10:40:44 AM
I'd suggest everyone that its a good company to invest in!
1. Mandar Bhojane     Link|January 24, 2023 10:20:30 AM
I had taken a few shares of Family Care Hospitals and surprisingly i got good returns!